Method of correction of antioxidant activity of liquid part of blood of newborn calves with iron deficiency anemia

FIELD: veterinary medicine.

SUBSTANCE: calves are injected intramuscularly as a single dose the solution of ferroglucine-75 on the basis of 15 mg of iron per 1 kg of live weight of a calf, and glicopin is fed 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection of ferroglucine-75.

EFFECT: method enables to normalise the antioxidant activity of the liquid part of the blood of newborn calves with iron deficiency anemia, to increase the reactivity of the animal organism, to reduce the risk of thrombotic complications, promotes normal growth and development of calves.

2 ex

 

The invention relates to biology and veterinary medicine, namely to Hematology.

Analogues of the proposed correction method the antioxidant activity (AOA) of the liquid portion of the blood of newborn calves with iron deficiency anemia does not exist.

In the literature there is information on the application of anemia in calves feroglobin (Internal non-infectious diseases of farm animals. Under. edit Vmenyaemogo. M: "Agropromizdat", 1991. - 576 S.).

In the literature, there are also recommendations on the use of animals for the purpose of immunostimulation of glicerina (N-acetylglucosaminyl-N-acetyl-muramyl-alanyl-D-isoglutamine) (Andronov T.M., Pinegin B.V., goats I.G., Ustinov GI Application immunomodulator of glicerina for the prevention and treatment of animal diseases. Methodical recommendations. Moscow, 2009. - 12 S.). But never before picopen and especially its combination with ferroaluminum was not used in newborn calves with iron deficiency anemia with the purpose of correcting existing weakening of the AOA of the liquid portion of blood that can cause the generation of a great amount of free radicals, leading to oxidative stress, a sharp worsening of the underlying disease and weakening of the reactivity of a living organism.

The aim of the invention is the normalization of antioxidant activity of liquid blood novorozhden the x calves with iron deficiency anemia.

The essence of the proposed method lies in the fact that for the correction of the AOA of the liquid portion of blood (plasma) of newborn calves with iron deficiency anemia intramuscularly once assigned solution feroglobin-75 (1 ml)containing 75 mg of iron per 1 ml of solution at a ratio of 15 mg of iron per 1 kg of body weight of the calf and feeding of glicerina at 6.0 mg/day in the morning (diluted in a small amount (100,0-of 150.0 ml) of water or milk or colostrum, designed to feed calves) for 6 days, starting simultaneously with the injection feroglobin-75.

The method is as follows. The calf is taken 5,0 blood from a vein and evaluated the antioxidant activity of the liquid portion of blood (Valigorsky I.A., Dolgushin, I.N., Kolesnikov O.L., Zelikman VE Experimental simulation and laboratory evaluation of adaptive reactions of the organism. Chelyabinsk, 2000. - 167 C.), which is the indicator that indirectly characterizing the antioxidant activity of the animal organism. For these purposes it is necessary to apply a pre-prepared drugs United homogenate marrow obtained from 5-6 rats. The brain of each animal homogenized in 10 ml of physiological solution and free from large particles by centrifugation followed by filtration through cheesecloth. The mixture obtained supernatant stored in a frozen state. Thus prepared, the drug is suitable DL the determination of antioxidant activity for two weeks.

Two tubes contribute to 1.79 ml isotonic sodium phosphate buffer (pH 7.4). Then one of them (control), add 1 ml of 28% trichloroacetic acid (THU) from 0.1% ethylene-diamine-tetraoxane acid (EDTA), 0.2 ml of the homogenate of the brain and 0.01 ml of the investigated biological fluid. In the second test tube (experienced) make the same amount of homogenate and the test fluid, the test tube is incubated in the conditions of access of air at 37C for 60 minutes, after which induced lipid peroxidation stopped by the addition of 1 ml of THU with EDTA.

In parallel to evaluate the oxidation used homogenate in the absence of the investigated biological fluid (instead of in a test tube add 0.01 ml of sodium phosphate buffer, otherwise the stroke determination is not changed).

The AOA is estimated by the degree of suppression of lipoperoxidation in vitro in the presence of biological fluids. The calculation is conducted according to the formula: AAO=100% [1-(SW;60-EO;0)/(CC;60-Ek;0)], where EC;60 and the EC;0 - values of optical density after 60 minutes of incubation and at "zero" time for samples containing the studied biological fluid, and SW;60 and SW;0 similar values of extinction for samples not containing the studied biological fluid. Normal values of AOA for newborn calves range from 34,0% to 42.0%.

For the correction reduced the antioxidant activity of the organism in Novgorod is the R calves with iron deficiency anemia once assigned feroglobin-75 (1 ml), containing 1 ml of a solution of 75 mg of iron at the rate of 15 mg of iron per 1 kg of body weight of the calf, and the feeding of glicerina at 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection feroglobin-75.

The method allows to normalize the antioxidant activity of the liquid portion of the blood of newborn calves with iron deficiency anemia on the next day after the end of treatment, bringing it to the level characteristic of healthy animals, which increases the reactivity of the organism of the animal and the treatment of the underlying disease that significantly reduce the risk of thrombotic complications, promoting normal growth and development of animals.

Example 1. Calf No. 116, the 3rd day of life, the body weight of 27.0 kg with iron deficiency anemia were examined in terms of the calf. The calf was taken and examined the blood with the assessment of the AOA, which was reduced to 19%.

Calves assigned to 5.4 ml feroglobin-75 intramuscularly once and feeding diluted to 100.0 ml milk glicerina at 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection feroglobin-75, which allowed for the following day after the end of correction to raise the AOA to normative values is 37.0%, eliminating the risk of weakening thereafter.

In further contain this calf was recommended on rational diet for Professor the prevention of the recurrence of the deficiency and the weakening of the AOA of the liquid portion of blood.

Example 2. Calf No. 119, the fourth day of life, body weight 31.5 kg, with iron deficiency anemia were examined in terms of the calf. The calf was taken and examined the blood with the assessment of the AOA, which was reduced to 27%. Calves assigned to 6.3 ml feroglobin-75 intramuscularly once and feeding diluted in 150,0 ml milk glicerina at 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection feroglobin-75, which allowed for the following day after the final correction to raise the AOA to the normative values of 39%, eliminating the risk of weakening thereafter.

In further contain this calf was recommended on rational diet to prevent recurrence of the deficiency and the weakening of the AOA of the liquid portion of blood.

The claimed method is tested on 145 newborn calves with iron deficiency anemia, showing 100% of cases the efficiency of correction of iron deficiency anemia and level of the AOA of the liquid portion of blood.

The correction method the antioxidant activity of the liquid part of the blood of newborn calves with iron deficiency anemia, including the use of a solution feroglobin-75 at the rate of 15 mg of iron per 1 kg of body weight of the calf intramuscularly once daily in combination with oral application of glicerina at 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection feroglobin-75.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: present invention relates to dihydropyrazolone derivatives or of formula (I), where R1 denotes a heteroaryl group of formulae given below, where * denotes the linkage point with the dihydropyrazolone ring, A in each individual occurrence denotes C-R4 or N, wherein at most two ring members A represent N at the same time, E denotes O or S, R2, R3 and R4 are as defined in the claim. The invention also relates to a method of producing said compounds.

EFFECT: compounds of formula (I) inhibit HIF-propylhydroxylase activity and can be used to treat and/or prevent diseases, as well as for producing medicaments for treating and/or preventing diseases, particularly cardiovascular and haematologic diseases, kidney diseases, and for promoting the healing of wounds.

10 cl, 10 tbl, 178 ex

FIELD: medicine.

SUBSTANCE: what is offered is using cyproheptadine as an agent preventing developing disorders in pulmonary tissue and blood system caused by the introduction of cytostatics. It is shown that cyproheptadine prevents alveoli infiltration, oedema of interalveoral septum, connective tissue development in lungs with reducing blood lymphocyte count and peripheral blood and bone marrow neutrophilic granulocyte count.

EFFECT: invention may be used for pharmacological correction of pulmonary fibrosis and blood system disorders developing with prescribing anticancer preparations.

1 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacology and medicine and concerns the use of dihydrobromide 9-(2-diethylaminoethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole of formula as a biologically active compound possessing high antihypoxic, actoprotective, nootropic activities and having a positive effect on physical efficiency, and a based pharmaceutical composition.

EFFECT: preparing the compound possessing high antihypoxic, actoprotective, nootropic activities and having a positive effect on physical efficiency, and the based pharmaceutical composition.

2 cl, 8 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 solution in dose 15 mg of iron per 1 kg of live weight of calf body, one time, intramuscularly and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: method makes it possible to stably normalise thrombotic hemostasis in newborn calves with iron-deficient anemia, ensures long-time support of thrombotic hemostasis in optimal mode of functioning, excludes risk of thrombotic complications and assists normal growth and development of calves.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 in dose 15 mg of iron per 1 kg of live weight of calf intramuscularly, one time and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: claimed method makes it possible to avoid vascular complications in newborn calves with iron-deficient anemia, make the herd healthier, reduce murrain, increase volume and quality of obtained meat and milk production, obtain healthy offspring from the animals.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes the pyrrolo- and thiazolopyridinium compounds and their pharmaceutically acceptable salts covered by general structural formula I: wherein the values A, B, R1, R2, R3, R4, R5, R6, R7 and R8 are those as presented in cl.1, and a pharmaceutical composition based on the given compound for inhibition of hypoxia-inducible factor (HIF) hydroxylase activity.

EFFECT: there are produced and described new compounds able to modulate hypoxia-inducible factor (HIF) stability and/or activity.

29 cl, 178 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to novel cyanoisoquinoline derivatives of formula I , where R is selected from a group comprising hydrogen and C1-C10 alkyl, R1, R2, R3 and R4 are independently selected from a group comprising hydrogen, halogen, hydroxy, C1-C10 alkyl, substituted with 1-3 halogen atoms or C6-C14 acryl, C6-C14 aryl, -OR7, -SR7 and -SO2R7, where R7 is selected from a group comprising C1-C10 alkyl, C1-C10 alkyl substituted with C6-C14 aryl, C3-C10 cycloalkyl, C6-C14 aryl and C7-C8 heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C6-C14 aryl and C7-C8 heteroaryl are optionally substituted with 1-3 substitutes selected from a group comprising halogen, C1-C6 alkoxy, C1-C10 alkyl, C1-C6 dialkylamino and C4 heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, and R5 and R6 are independently selected from a group comprising hydrogen and C1-C3 alkyl, or pharmaceutically acceptable salts thereof. The invention also relates to novel cyanoquinoline derivatives of formula II , where R31, R32, R33 and R34 are independently selected from a group comprising hydrogen, hydroxy, halogen, C1-C10 alkyl substituted with 1-3 halogen atoms or with C6-C14 aryl, C6-C14 aryl, -OR37, -SR37 and -SO2R37, where R37 is selected from a group comprising C1-C10 alkyl, C1-C10 alkyl substituted with C6-C14aryl, C3-C10 aryl, C7-C8 heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C6-C14 aryl and C7-C8 heteroaryl are substituted with 1-3 substitutes selected from a group comprising halogen, C1-C6 alkoxy, C1-C10 alkyl, C1-C6 dialkylamino C4 heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, R35 denotes hydrogen or methyl, or pharmaceutically acceptable salts thereof. The invention also relates to specific cyanoisoquinoline compounds, a pharmaceutical composition based on the compound of formula I, a hypoxia-inducible factor (HIF) hydroxylase inhibiting method, a method of treating, preventing or slowing down development of a condition associated with hypoxia-inducible factor (HIF), a condition associated with erythropoietin (EPO), anaemia, based on use of the compound of formula I.

EFFECT: obtaining novel cyanoisoquinoline compounds having useful biological properties.

42 cl, 1 tbl, 54 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to an oral food additive which contains anhydrous ferric pyrophosphate, ferric pyrophosphate monohydrate or nonahydrate and copper citrate. The invention also concerns a method for preparing said additive and using it for balanced iron intake in the patient.

EFFECT: additive under the invention has no unpleasant metal taste even in the absence of flavouring and taste masking ingredients.

19 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science. The preparation contains a mixture of colloidal iron, a ligand, zinc, cobalt, selenium and water. The ligand is presented by Triton X-100 (polyethylene glycol mono (tetramethylbutanol) phenyl ester) in the following proportions, mg: colloidal iron (III) 35.0-45.0; Triton X-100 0.20.6; zinc (II) 0.10.3; cobalt (II) 0.050.15; selenium (IV) 0.020.04 and water up to 1000.0.

EFFECT: preparation exhibits high therapeutic and preventive efficacy, low toxicity, keeps dispersion and shows high storage stability.

5 cl, 12 tbl, 13 ex

FIELD: chemistry.

SUBSTANCE: invention relates to pharmaceuticals and medicine and pharmaceutically acceptable derivatives of 2-aminobenzothiazole of general formula 1.

EFFECT: high anti-hypoxic activity and high effectiveness of treatment.

7 cl, 3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 solution in dose 15 mg of iron per 1 kg of live weight of calf body, one time, intramuscularly and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: method makes it possible to stably normalise thrombotic hemostasis in newborn calves with iron-deficient anemia, ensures long-time support of thrombotic hemostasis in optimal mode of functioning, excludes risk of thrombotic complications and assists normal growth and development of calves.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 in dose 15 mg of iron per 1 kg of live weight of calf intramuscularly, one time and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: claimed method makes it possible to avoid vascular complications in newborn calves with iron-deficient anemia, make the herd healthier, reduce murrain, increase volume and quality of obtained meat and milk production, obtain healthy offspring from the animals.

2 ex

FIELD: medicaments.

SUBSTANCE: present invention provides water-soluble iron-carbohydrate derivative complexes which are suitable for the therapy of iron deficiency states, and the preparation thereof, medicaments comprising them, and the use thereof in the prophylaxis or therapy of iron deficiency states. The medicaments are suitable in particular for parenteral administration. A water-soluble iron-carbohydrate derivative complex obtained from the reaction of an aqueous iron (III) salt solution and (b) an aqueous solution of the product of the oxidation and subsequent derivatization of one or more maltodextrins, wherein the oxidation is carried out with an aqueous hypochlorite solution at a pH value in the alkaline range, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40, and the subsequent derivatization is carried out with a suitable reagent. The process for the preparation of the iron-carbohydrate complex, wherein one or more maltodextrins is oxidized in aqueous solution, at an alkaline pH value, with an aqueous hypochlorite solution, the subsequent derivatization is carried out with a suitable reagent, and the resulting solution is reacted with the aqueous solution of an iron (III) salt, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40.

EFFECT: most derivatised maltodextrin ligands exhibit increased stability towards enzymatic degradation by amylase as compared with underivatised maltodextrin, which can promote retarded and uniform degradation of the iron-maltodextrin derivative complexes according to the invention in the body.

15 cl, 11 tbl, 45 ex

FIELD: pharmacology.

SUBSTANCE: invention refers to binuclear cation nitrosyl iron complexes with natural aliphatic thiolyls with general formula [Fe2(SR)2(NO)4]SO4 where R is aliphatic ligands of natural origin.

Also there is proposed method for production of binuclear cation nitrosyl iron complex, nitrogen monoxide donor, inductor of tumor cells apoptosis, application binuclear cation nitrosyl iron complex, pharmaceutical composition and set used for treatment of oncology diseased. The technical result is EFFECT: production of binuclear cation nitrosyl iron complex possessing cytotoxic, apoptotic and NO-donor activity.

15 cl, 2 ex, 4 tbl, 7 dwg

FIELD: pharmacology.

SUBSTANCE: invention refers to binuclear nitrosyl iron complexes with benzazeheterocyclic derivatives with general formula [Fe2(SR)2(NO)4] where R is And where X is NH, S, R1 is lower alkyl. Also there is proposed method for its production, nitrogen monoxide donor, application as oncology drug and for production of oncology drug, pharmaceutical composition and set used for treatment of oncology diseased.

EFFECT: production of binuclear nitrosyl iron complex that is used as an oncology drug with increased effectiveness and decreased toxicity.

15 cl, 3 ex, 4 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine and chemical-pharmaceutical industry, in particular, to medication, applied in case of myocardial infarction and operations on heart in conditions of artificial blood circulation. Water-soluble composition for intravenous introduction, contains ingredients with the following component ratio in wt %: D-glucose 23.40-28.60; potassium chloride 0.14-0.16; potassium salt of L-asparaginic acid 0.81-0.99; semi-magnesium salt of L-asparagenic acid (magnesium L-aspartate) 0.72-0.88; human insulin genetically engineered (in IU/l) 54.00-66.00; dinitrosyl complex of iron (II) with glutathione 0.19-0.23; water for injections - remaining part, with solution pH 7.40.1 at 22C.

EFFECT: application of composition ensures limitation of myocardial infraction size, recovery of metabolic condition of heart at reperfusion, reduces injury of membranes of post-ischemic cardiomyocytes with smaller haemodinamics disorders as compared with traditionally applied medications.

2 dwg, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to use of a tetranitrosyl complex of iron with thiophenol of formula [Fe2(SC6H5)2(NO)4] as an anti-tumour medicinal agent in order to prepare a medicinal agent for treating oncological diseases. The invention also relates to a pharmaceutical composition and a set containing said complex.

EFFECT: invention ensures high efficiency of treatment.

8 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to complex compound of iron with carbohydrate. Complex compound, in addition to iron (III) contains iron (II). Per cent of iron (II) in terms of total amount of iron in complex compound constitutes, at least, 2 wt %. Carbohydrate is selected from group, consisting of natural carbohydrates or synthetic derivatives of carbohydrates, such as starch, hydrolysed starches, dextrins, in particular such as maltodextrin, maltose syrup, glucose syrup, cyclodextins, dextrans, saccharides. Per cent of carbohydrate in terms of complex compound of iron with carbohydrate constitutes from 10 to 80 wt %. Method of obtaining complex compound of iron with carbohydrate includes the following stages. Water solution of suspension of carbohydrate is prepared. After that, iron (III) salts are added at constant pH value within the range from 7 to 13. Iron (III) salt is selected from group, consisting of iron (III) chloride and iron (III) sulfate. Water solution or suspension is heated with further cooling. Formed complex compound of iron with carbohydrate if isolated. Precipitation of complex compound of iron with carbohydrate is performed by addition of one or more alcohols, such as ethanol or propanol. Obtained complex compound is used for production of medication for treatment of iron-deficient anemias, which is well absorbed in organism in case of peroral intake.

EFFECT: iron, included into composition of medication is better resorbed and better tolerated by organism than pure iron preparations.

26 cl, 1 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics, in particular deals with composition with prolonged release of active substance, representing iron source, containing at least one coated granule, said coated granule consisting of particle, which contains said active substance, covered with at least two coats, containing combination of excipients, as well as to method of obtaining it. Claimed compositions can be used for obtaining medication, intended for treatment and/or prevention of iron deficiency and anemia, induced by iron deficiency.

EFFECT: invention provides composition with prolonged release of active substance, possessing high stability and ensuring protection of active substance from oxidation.

30 cl, 2 ex, 3 dwg

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves three intramuscular introduction of ferroglucin 75 mg (1 ml) every 5 days, three intramuscular introduction of phosprenyl by different syringes in different points simultaneously with an iron preparation, 0.12 ml/kg for the first injection, 0.10 ml/kg for the second injection, 0.08 ml/kg for the third injection, and the intramuscular injections of gamavit 0.018 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows to prevent vascular complications in newborn calves with anaemia, to optimise microcirculation and tissue trophism, to hasten the growth, to improve a herd, to produce greater amount of meat production, to produce an expected healthy posterity from these animals.

1 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical oral dosage form contains a mixture treated in a melt and consisting of one active ingredient which represents a solid dispersion, at least one pharmaceutically acceptable polymer and a solubilising composition containing at least one tocopheryl-containing compound and at least one propylene glycol monofatty acid ester or a mixture of propylene glycol mono- and difatty acid esters. The active ingredient (ingredients) may be presented by a HIV protease inhibitor. The invention also refers to a method for preparing said pharmaceutical form which consists in preparing a homogenous melt of said active ingredient, said pharmaceutically acceptable polymer, and said solubilising composition, and making the melt to harden to form a solid disperse product.

EFFECT: solubilising composition provides higher biological availability of the active ingredient after the oral introduction.

Up!